• Acquisition of Stemline estab­lishes Menarini’s presence in the U.S. bio­pharma­ceu­tical on­col­ogy mar­ket
• Menarini will sup­port fur­ther de­vel­op­ment of Stemline’s ELZONRIS® and enable global ex­pan­sion by leveraging its com­mer­cial infrastructure in Europe and other ex-U.S. geographies
• Following the trans­action, Menarini will con­tinue to re­search ELZONRIS in addi­tional CD123-expressing in­di­ca­tions

Florence, Italy (Press Release) – Menarini Group, a privately held Italian pharma­ceu­tical and diagnostics com­pany, to­day an­nounced that is has suc­cess­fully com­pleted the ac­qui­si­tion of Stemline Thera­peutics Inc., a com­mer­cial-stage bio­pharma­ceu­tical com­pany focused on the de­vel­op­ment and com­mer­cial­i­za­tion of novel on­col­ogy thera­peutics (Nasdaq: STML), for an aggregate cash con­sid­er­a­tion up to $677 million on a fully diluted basis.

The trans­action, which was an­nounced on 4 May 2020, strengthens Menarini’s on­col­ogy port­folio with the addi­tion of both com­mer­cial and clin­i­cal-stage assets. Menarini acquired Stemline for an up­front …

• Acquisition of Stemline estab­lishes Menarini’s presence in the U.S. bio­pharma­ceu­tical on­col­ogy mar­ket
• Menarini will sup­port fur­ther de­vel­op­ment of Stemline’s ELZONRIS® and enable global ex­pan­sion by leveraging its com­mer­cial infrastructure in Europe and other ex-U.S. geographies
• Total poten­tial con­sid­er­a­tion of $12.50 per share comprising $11.50 cash and $1.00 Contingent Value Right (CVR)

Florence, Italy and New York, NY (Press Release) – Menarini Group, a privately held Italian pharma­ceu­tical and diagnostics com­pany, and Stemline Thera­peutics Inc., a com­mer­cial-stage bio­pharma­ceu­tical com­pany focused on the de­vel­op­ment and com­mer­cial­i­za­tion of novel on­col­ogy thera­peutics, (Nasdaq: STML) to­day an­nounced a definitive agree­ment under which Menarini Group will acquire Stemline in a trans­action valued up to $677 million.

Under the terms of the agree­ment, a wholly owned sub­sid­i­ary of the Menarini Group will com­mence a tender offer for all out­stand­ing shares …

New York (Press Release) - Stemline Thera­peutics, Inc. (Nasdaq:STML) an­nounced to­day that data demonstrating SL-401 ef­fi­cacy in mul­ti­ple myeloma (MM) pre­clin­i­cal models will be pre­sented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2014 in Chicago, IL.

In col­lab­o­ration with Stemline, ex­per­i­ments con­ducted at the Dana-Farber Cancer In­sti­tute, Boston, MA, by Drs. Dharminder Chauhan and Kenneth Anderson and their MM re­search team dem­onstrated that Stemline's clin­i­cal can­di­date SL-401 sig­nif­i­cantly de­creased the viability of malignant cells by targeting neighboring plas­ma­cytoid dendritic cells (pDCs) in the tumor …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which im­por­tant new re­search findings were summarized on posters dis­played throughout a large conference hall.

The stud­ies pre­sented during the session were on a wide variety of myeloma-related topics, in­clud­ing new treat­ments being devel­oped for myeloma, cur­rently used regi­mens, smol­der­ing mul­ti­ple myeloma, and findings on initial ther­apy.

Some of the posters in­cluded pre­lim­i­nary results from on­go­ing clin­i­cal trials.  Others described the design …

The American Society of Clinical Oncology will hold its 49^th annual meeting May 31 through June 4 in Chicago.

Similar to pre­vi­ous years, more than 25,000 clin­i­cal spe­cialists from all over the world are ex­pec­ted to attend the five-day meeting to discuss the cur­rent re­search in cancer treat­ment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”

During the meeting, there will be pre­sen­ta­tions and seminars about all areas of cancer, in­clud­ing many focused spe­cif­i­cally on mul­ti­ple myeloma. The ASCO website cur­rently lists more than 60 myeloma-based pre­sen­ta­tions (included …